View Details on the Top 20 Companies With Products in the Early Stage of Development for Non-Small-Cell Lung Cancer, Lung Cancer or Small Cell Lung Cancer
Posted on: Friday, 24 August 2007, 12:13 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c66631) has announced the addition of "Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report" to their offering.
"Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of non-small-cell lung cancer or lung cancer or small cell lung cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits:
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
For more information visit http://www.researchandmarkets.com/reports/c66631
Source: Life Science Analytics
Source: Business Wire
Related Articles
- Lung Cancer Cells Activate Inflammation To Induce Metastasis
- Pfizer Shows Accelerating Pipeline With Significant Growth in Late-Stage Clinical Development
- Microchip to Aid Lung Cancer Treatments
- ArQule Initiates Phase I/II Trial for Lung Cancer Drug
- PhytoMedical's Patented Anti-Cancer Compounds Kill Lung Cancer Cells, a Significant New Finding
- Breath Test Detects Lung Cancer in Early Stages
- Unique Structure of Geron's Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells
- Biomira Lung Cancer Vaccine Enters Late Stage Trial
- Thermal Ablation Treats Some Lung Cancer
- Antitumor Activity Shown for 2ME2 and Analogs in Preclinical Lung Cancer Models
 |
 |
User Comments (0)
RSS Feeds